This abstract, presented at the 2021 ICAR virtual conference, reports on a novel dihydroorotate dehydrogenase (DHODH) inhibitor as a possible treatment for COVID-19
ICAR 2021 abstract: The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines implicated in severe COVID-19 disease and is currently being evaluated in the FITE19 clinical trial in hospitalized patients
GL-CORP-0207 | June 2021
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.